Jacob Elkins

Statistics

Publications

Citations

4.4K

H-Index

Active since

2000

Affiliations

Biogen (United States)(Current)

AbbVie (United States)

Queen Mary University of London

Rice University

Medical University of Lodz

Jacob Elkins is an author at Biogen (United States) specializing in neurology, multiple sclerosis, and relapsing-remitting multiple sclerosis treatment.

ORCID

Publications per year

2000–2025

Publications

Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack

S. Claiborne Johnston, Peter M. Rothwell, Mai N. Nguyen‐Huynh et al. · The Lancet · 2007 · 1.3K citations

Medicine, Neurology, Early Detection +12

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Daniel Wynn, Michael D. Kaufman, Xavier Montalbán et al. · The Lancet Neurology · 2010 · 300 citations

Life Sciences, Neurology, Pharmacotherapy +10

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj et al. · The Lancet · 2013 · 287 citations

Life Sciences, Neurology, Pharmacotherapy +9

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Ludwig Kappos, Heinz Wiendl, Krzysztof Selmaj et al. · New England Journal of Medicine · 2015 · 265 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

Jacob Elkins, Roland Veltkamp, Joan Montaner et al. · The Lancet Neurology · 2017 · 214 citations

Medicine, Neurology, Pharmacology +11

1–5 of 47